by Maria Zannes | Dec 3, 2025 | Press Releases
SAN ANTONIO, Texas – December 3, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will...
by Maria Zannes | Dec 2, 2025 | Publications
American Cancer Society National Lung Cancer Roundtable, December 7, 2025 Author: Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer. Three patient case studies in which CyPath® Lung, a noninvasive sputum-based flow cytometry test,...
by Maria Zannes | Nov 14, 2025 | Press Releases
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO, Texas – November 14, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of...
by Maria Zannes | Nov 5, 2025 | Press Releases
October test volume 111% more than 2025 year-to-date monthly average SAN ANTONIO, Texas — November 5, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today...
by Maria Zannes | Oct 28, 2025 | Press Releases
Australian patent strengthens global patent portfolio SAN ANTONIO, TX — October 28, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung...
